TheraRadar
← Back
Data updated: Jun 28, 2026

CHATTEM SANOFI

Big Pharma
MetabolicOncologyCardiovascular Execution: Good

CHATTEM SANOFI is a major pharmaceutical company focused on Metabolic, Oncology, Cardiovascular. Key products include XYZAL ALLERGY 24HR.

1983
Since
15
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
6 Small Molecules

CHATTEM SANOFI at a Glance

  • Fast trial execution (19 months median completion)

CHATTEM SANOFI's Key Drugs

CHATTEM SANOFI's core commercial portfolio centers on XYZAL ALLERGY 24HR, spanning Metabolic and Oncology — its most strategically important drugs approved in the last 15 years.

XYZAL ALLERGY 24HR
Respiratory
Approved 2017

CHATTEM SANOFI's Recent FDA Approvals

New NDA/BLA approvals for CHATTEM SANOFI over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

CHATTEM SANOFI's Therapeutic Areas

CHATTEM SANOFI's approved drugs and pipeline span 5 therapeutic areas, led by Metabolic and Oncology, across 0 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 37%
0 drugs Phase 3: 69 Phase 2: 11 Phase 1: 99
Oncology 30%
0 drugs Phase 3: 32 Phase 2: 49 Phase 1: 88
Cardiovascular 13%
0 drugs Phase 3: 27 Phase 2: 8 Phase 1: 15
Immunology 11%
0 drugs Phase 3: 14 Phase 2: 21 Phase 1: 19
Respiratory 9%
0 drugs Phase 3: 15 Phase 2: 14 Phase 1: 9

CHATTEM SANOFI Pipeline Snapshot

CHATTEM SANOFI has 490 active clinical programs from ClinicalTrials.gov — 157 Phase 3, 103 Phase 2 and 230 Phase 1.

157
Phase 3
103
Phase 2
230
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • XYZAL ALLERGY 24HR leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Metabolic pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 224/312 completed
  • • Speed: 19 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges